Drug intelligence / Profile preview

CA12-targeted radioimmunotherapy

Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intratumoral
01

Overview

CA12-targeted radioimmunotherapy is an investigational targeted radionuclide therapy (radioimmunotherapy) approach designed for the treatment of solid tumors, particularly glioblastoma. The therapy targets carbonic anhydrase XII (CA12 or CA XII), a transmembrane enzyme overexpressed in hypoxic and acidic tumor microenvironments but largely absent in healthy brain tissue. The primary clinical candidate representing this platform is ITM-31 (formerly LuCaFab), which consists of a CA12-specific monoclonal antibody Fab fragment (6A10-Fab) conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Administered directly into the post-surgical resection cavity (intracavitary), the therapy bypasses the blood-brain barrier to deliver localized, cytotoxic beta radiation directly to residual glioblastoma cells, aiming to eliminate micro-metastases and prevent tumor recurrence while sparing surrounding healthy brain tissue.

Other names
177Lu-6A10-Fab[177Lu]Lu-6A10-FabCA12-targeted radioimmunotherapyCA-12-targeted radioimmunotherapyCA 12-targeted radioimmunotherapyLu-177 labeled 6A10-Fab-fragmentsLu177 labeled 6A10-Fab-fragmentsLu 177 labeled 6A10-Fab-fragments
02

Identity

Drug type
Antibody-Based Therapeutics
Originator
Helmholtz Munich
Modality
Antibody FragmentsAntibody-Radionuclide Conjugates
Synonyms and codes
ITM-31
03

Pharmacology

Route
Intratumoral
04

Development

IndicationHighest phaseStatus
glioblastoma, IDH-wildtypeIn developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
13
Drugs in the lead indication
709

Lead indication: glioblastoma, IDH-wildtype

Most advanced in the lead indication

  1. bevacizumabApproved
  2. carmustineApproved
  3. chlortalidonApproved
  4. dichlorphenamideApproved
  5. mafenideApproved

Beyond the preview

Go deeper on CA12-targeted radioimmunotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CA12-targeted radioimmunotherapy.

Work on CA12-targeted radioimmunotherapy? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call